- Home
- SUPN vs REVG Comparison
SUPN vs REVG Comparison
Compare SUPN & REVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- REVG
- Stock Information
- Founded
- SUPN 2005
- REVG 2008
- Country
- SUPN United States
- REVG United States
- Employees
- SUPN N/A
- REVG N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- REVG Auto Manufacturing
- Sector
- SUPN Health Care
- REVG Consumer Discretionary
- Exchange
- SUPN Nasdaq
- REVG Nasdaq
- Market Cap
- SUPN 2.6B
- REVG 2.9B
- IPO Year
- SUPN 2012
- REVG 2017
- Fundamental
- Price
- SUPN $54.61
- REVG $61.43
- Analyst Decision
- SUPN Strong Buy
- REVG Hold
- Analyst Count
- SUPN 3
- REVG 4
- Target Price
- SUPN $62.67
- REVG $53.00
- AVG Volume (30 Days)
- SUPN 725.2K
- REVG 587.1K
- Earning Date
- SUPN 11-04-2025
- REVG 12-10-2025
- Dividend Yield
- SUPN N/A
- REVG 0.39%
- EPS Growth
- SUPN 1411.53
- REVG N/A
- EPS
- SUPN 1.14
- REVG 2.12
- Revenue
- SUPN $665,125,000.00
- REVG $2,397,000,000.00
- Revenue This Year
- SUPN $7.31
- REVG $4.82
- Revenue Next Year
- SUPN $21.87
- REVG $8.06
- P/E Ratio
- SUPN $46.18
- REVG $28.74
- Revenue Growth
- SUPN 5.55
- REVG N/A
- 52 Week Low
- SUPN $29.16
- REVG $25.76
- 52 Week High
- SUPN $53.28
- REVG $64.47
- Technical
- Relative Strength Index (RSI)
- SUPN 78.22
- REVG 66.91
- Support Level
- SUPN $49.95
- REVG $57.91
- Resistance Level
- SUPN $52.15
- REVG $61.68
- Average True Range (ATR)
- SUPN 1.36
- REVG 1.63
- MACD
- SUPN 0.30
- REVG 0.47
- Stochastic Oscillator
- SUPN 97.61
- REVG 96.79
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About REVG REV Group Inc.
REV Group Inc is a United States-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services. During the first fiscal quarter of 2024, the Company formed the Specialty Vehicles Segment by combining the Fire & Emergency and Commercial segment businesses. Additionally, the Recreation segment was renamed Recreational Vehicles. As a result, the Company is now organized into two reportable segments. The company operates in the United States, Canada, and the rest of the world. Maximum of revenue is gained from Specialty Vehicles Segment.